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Abstract
Background: Antipsychotics are divided into typical and atypical compounds based on clinical
efficacy and side effects. The purpose of this study was to characterize in vitro a series of novel
azecine-type compounds at human dopamine D1-D5 and 5HT2A receptors and to assign them to
different classes according to their dopamine/5HT2A receptor profile.
Results: Regardless of using affinity data (pKi values at D1-D5 and 5HT2A) or selectivity data (15
log (Ki ratios)), principal component analysis with azecine-type compounds, haloperidol, and
clozapine revealed three groups of dopamine/5HT2A ligands: 1) haloperidol; 2) clozapine plus four
azecine-type compounds; 3) two hydroxylated dibenzazecines. Reducing the number of Ki ratios
used for principal component analysis from 15 to two (the D1/D2 and D2/5HT2A Ki ratios) obtained
the same three groups of compounds. The most potent dibenzazecine clustering in the same group
as clozapine was the non-hydroxylated LE410 which shows a slightly different D2-like receptor
profile (D2L > D3 > D4.4) than clozapine (D4.4 > D2L > D3). The monohydroxylated dibenzacezine
LE404 clusters in a separate group from clozapine/LE410 and from haloperidol and shows increased
D1 selectivity.
Conclusion: In conclusion, two compounds with a novel dopamine/5HT2A receptor profile, LE404
and LE410, with some differences in their respective D1/D2 receptor affinities including a validated
pharmacophore-based 3D-QSAR model for D1 antagonists are presented.
Background
Dopamine is an important neurotransmitter in the mam-
malian CNS which has influence on physiological, behav-
ioural and neuroendocrine functions, mediated through
receptors on the cell surface. Five different dopamine
receptor subtypes have been cloned and characterized.
They belong to the super-family of G protein-coupled
receptors (GPCR) and can be divided into two sub-
families, D1-like (D1, D5) and D2-like (D2, D3, D4) recep-
tors, according to their sequence homologies,
biochemical properties, and pharmacologic profiles [1].
D1-like receptor stimulation activates adenylyl cyclase
(AC) via coupling to stimulatory G protein Gαs/Gαolf sub-
units leading to an increase in intracellular cAMP concen-
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trations. In contrast, D2-like receptors are Gαi/Gαo linked
and inhibit AC activity [2]. Dopamine receptors are clini-
cally important drug targets for the treatment of disorders
such as Parkinson's disease and schizophrenia [3]. Block-
ade of dopamine D2 receptors is the main feature of antip-
sychotic action. Typical antipsychotics like the first
generation D2 receptor antagonists haloperidol or chlo-
rpromazine can cause therapy-limiting extrapyramidal-
motor side effects (EPS). Second generation (atypical)
antipsychotics are serotonin/dopamine antagonists with
no or low EPS at doses showing antipsychotic activity and
have significantly greater affinity for 5HT2A than for D2
receptors [4]. This serotonin-dopamine ratio could con-
tribute to atypicality [5-7] but further investigations are
needed to define the precise mechanism of atypical antip-
sychotics. However, antipsychotic activity is not only the
result of D2 and 5HT2A receptor blockade but an inhibi-
tory/modulating effect on various dopamine and serot-
onin (D1, D2, D3, D4, 5HT1A, 5HT1D, 5HT2A, 5HT2C) and
further receptors [8]. Within the heterogeneous group of
atypical antipsychotics, only clozapine exhibits effects
against treatment-resistant schizophrenia [9]. Responsible
for this net effect among atypical antipsychotics may be
the moderate affinity of clozapine at various receptor sub-
types, especially at D1-receptors. A dysfunction in D1-
receptor modulation in the prefrontal cortex contributes
to the negative symptoms and cognitive deficits observed
in schizophrenia. However, selective D1 antagonism alone
has not turned out as an effective antipsychotic principle
[9,10].
LE300, an indolobenzacezine (figure 1) has previously
been characterized [11] and shows a binding profile sim-
ilar to that of clozapine, however with a greater affinity for
D1- than D2-like receptors. A series of LE300-derived com-
pounds was recently synthesized and screened at
dopamine D1, D2L, and D5 receptors by a previously pub-
lished functional calcium assay [12,13]. The aim of the
current study was to investigate the comprehensive bind-
ing and functional receptor profile of the most active of
the dibenzazecine derivatives of LE300 (LE400, LE401,
LE403, LE404, LE410, and LE420, figure 1) at all human
dopamine and 5HT2A receptors, to test whether data from
the calcium assay initially used for screening of LE300-
derived compounds [13] correlate with other assays meas-
uring functional activation of GPCRs (cAMP, [35S]-
GTPγS), and to establish a 3D-QSAR pharmacophore
model of these ligands. Heterologous competition bind-
ing experiments were carried out at recombinantly
expressed human dopamine and 5HT2A receptors, and
obtained data were compared with functional data from
intracellular [cAMP] and [Ca2+] measurements and [35S]-
GTPγS-binding. Indeed, dibenzazecine compounds with a
previously not available receptor profile (increased antag-
onist activity at D1-like and 5HT2A receptors) were found.
3D-QSAR studies were performed resulting in QSAR mod-
els allowing further rational ligand design at a molecular
level.
Results
Receptor expression and characterization
Homologous radioligand competition binding experi-
ments were performed to determine the receptor expres-
sion levels (Bmax) and binding affinities (Kd) of the used
radioligands. Average Bmax and Kd values for each receptor
are shown in table 1. All Kd values except for 5HT2A recep-
tors were 3-6-fold higher than those found in the litera-
ture (table 1, [14-17]). This effect could be attributed to
the use of isotonic Krebs-HEPES-buffer pH 7.4 in this
study instead of the widely used TRIS-HCl buffer pH 7.4
in the literature. Figure 2 shows as an example the buffer-
dependent inhibition by LE300 of [3H]SCH23390 bind-
ing to D1  receptor membranes. Using Krebs-HEPES
instead of TRIS-HCl buffer yielded ~4-fold higher Ki val-
ues of LE300 (figure 2) but allowed a better comparison
of functional and binding data. A buffer-dependent
change of affinity was also observed with the test com-
pounds. However, the Kd ratios among the receptor sub-
types using Krebs-HEPES buffer were equal to literature
data using TRIS-HCl (not shown).
Radioligand binding studies
Binding affinities of the compounds LE300, LE400,
LE401, LE403, LE404, LE410, and LE420 (figure 1) were
estimated at recombinant dopamine and 5HT2A receptors
in cell membrane preparations. Further compounds used
for 3D-QSAR analysis of D1 receptor ligands (AHAD11,
B157, LERU301, SH3, figure 1) were tested at D1 receptors
only due to limited availability. For the sake of compari-
son, haloperidol as a classical antipsychotic, clozapine as
an atypical antipsychotic, and LE300 were included as ref-
erence compounds. Figure 3 shows the radioligand dis-
placement curves of the most potent hD1 and hD2L ligands
LE404 and LE410 at hD1 (A), hD2L (B), and 5HT2A (C)
receptors. pKi values are displayed in table 2 (LE300,
LE400, LE401, LE403, LE404, LE410, and LE420) and
table 3 (AHAD11, B157, LERU301, SH3).
All compounds showed similar affinities at hD1 and hD5
receptors. The mono-hydroxylated LE404 turned out as
the most potent compound at hD1/hD5 receptors with
pKi values of 8.47 and 8.53, respectively, followed by the
bis-hydroxylated LE403 which is 3-10-fold less potent
than LE404. Replacement of the hydroxy- by methoxy-
substituents resulting in LE400 dramatically decreased the
affinity at all tested receptors. An increase of the size of the
nitrogen substituent (allyl group of LE401) further
decreased the affinity at all tested receptors. Except LE400
and LE401, all other compounds possessed up to 33fold
(LE403, LE404) higher affinities for D1-like than for D2-BMC Pharmacology 2006, 6:11 http://www.biomedcentral.com/1471-2210/6/11
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like receptors (table 2). Among D2-like receptors, all com-
pounds – except LE404 – showed the highest affinity at
hD2L and lower affinities at hD3 and hD4.4 receptors
similar to the profile of haloperidol at D2-like receptors.
However, different to haloperidol which shows a strong
D2 over D1 selectivity, LE compounds (except LE400 and
LE401) show selectivity for D1 over D2. Removal of the
hydroxy-group of LE404 yielding LE410 resulted in a dra-
matic loss of D1 over D2 selectivity, and left LE410 as the
most potent compound at hD2L and hD3 receptors with
pKi values of 7.54 and 6.86, respectively. Bioisosteric
replacement of one benzene residue in LE410 by thi-
ophene gave LE420 showing a similar receptor profile as
LE410 but with reduced affinity at all tested receptors.
Table 1: Characterization of recombinantly expressed human dopamine and h5HT2A receptors in HEK293 cell membrane 
preparations
Kd Bmax Kd Literature
a)
Receptor nM fmol/mg protein nM
hD1 1.93 ± 0.24 3520 ± 790 0.35
hD2L 0.18 ± 0.02 1641 ± 462 0.06
hD3 0.84 ± 0.10 4060 ± 973 0.275
hD4.4 0.30 ± 0.06 493 ± 83.7 0.09
hD5 1.50 ± 0.23 1030 ± 263 0.30
h5HT2A 0.54 ± 0.07 165 ± 84.2 0.91
a) Data taken from [14-17]
[3H]SCH23390 was used for D1-like, [3H]spiperone for D2-like and 5HT2A receptors in homologous competition experiments. Data are mean ± 
SEM, n ≥ 3.
Structural formulas of the indolobenzazecine LE300, SCH23390, and a series of ten derived compounds Figure 1
Structural formulas of the indolobenzazecine LE300, SCH23390, and a series of ten derived compounds.
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LE404 displayed a receptor profile within the D2-like
receptors which is unique among the tested LE com-
pounds. Within the D2-like receptors, LE404 reached the
highest affinity at hD4.4 (pKi: 7.23), a slightly lower affin-
ity at hD2L (pKi: 7.10), and the lowest affinity at hD3
receptors (pKi: 6.73). The D2-like receptor affinity pattern
of LE404 is thus similar to clozapine (D4.4 ≥ D2L > D3).
In contrast to clozapine which appeared ~ equipotent at
D1/D2 receptors in all of our test systems, LE404 shows
25fold selectivity for D1 over D2. LE404 displayed higher
affinities than LE300 at all dopamine receptors except
hD2L where both compounds are ~ equipotent. All com-
pounds except LE401 showed the highest affinities among
all tested receptors at 5HT2A. The most potent compound
at 5HT2A was LE300 with an affinity in the subnanomolar
range followed by LE404 in the low nanomolar range.
LE300, LE400, LE403, LE404, LE410, and LE420 achieved
Ki-D2i-5HT2A /K selectivity ratios > 7.
Functional studies (cAMP, Ca2+ and [35S]-GTPγS binding) 
at hD1 and hD2L receptors
For functional studies, hD1 and hD2L receptors were cho-
sen as characteristic representatives of each of the two
dopamine receptor subtype groups allowing a compari-
son of functional and binding data. The inhibition by LE
compounds of agonist-induced changes in intracellular
[cAMP] and [Ca2+] in intact HEK293 cells, and [35S]-
GTPγS binding in HEK293 cell membranes were esti-
mated. Table 4 shows EC50 and IC50 values of standard lig-
Heterologous competition binding curves of LE404 (■) and  LE410 (●) at hD1 (A), hD2L (B), and 5HT2A (C) receptors Figure 3
Heterologous competition binding curves of LE404 
(■) and LE410 (●) at hD1 (A), hD2L (B), and 5HT2A 
(C) receptors. Data shown are the means ± SEM of specific 
binding of at least four determinations assayed in triplicate. 
A. 0.2 nM [3H]SCH23390 was used for hD1 receptors. Non-
specific binding was determined with 1 μM LE300. B. 0.1 nM 
[3H]spiperone was used for hD2L receptors. Nonspecific 
binding was determined with 1 μM haloperidol. C. 0.1 nM 
[3H]spiperone was used for h5HT2A receptors. Nonspecific 
binding was determined with 1 μM ketanserin.
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Buffer-dependent differences in hD1 receptor potencies of  LE300 in competition binding Figure 2
Buffer-dependent differences in hD1 receptor poten-
cies of LE300 in competition binding. Inhibition by 
LE300 of the binding of 0.2 nM [3H]SCH23390 to hD1 recep-
tor expressing HEK293 cell membranes using Krebs-HEPES 
buffer pH 7.4 (●) or TRIS-HCl pH 7.4 (❍), respectively. Hill 
slopes were not different from unity. Nonspecific binding was 
determined with 1 μM SCH23390, and was less than 7%. 
Data shown are mean ± SEM, n = 3. Ki (Krebs-HEPES): 10.0 
± 1.15 nM; Ki (TRIS-HCl): 2.36 ± 0.13 nM.
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ands at D1 and D2L receptors. The effects of LE compounds
on [35S]-GTPγS binding were determined in the presence
of agonist. At hD1 receptors the full agonist dihydrexidine
[18] was used for [35S]-GTPγS binding experiments
instead of SKF38393 which was used in cAMP and Ca2+
studies. In membrane preparations from HEK293-hD1
cells, dihydrexidine showed a significantly higher increase
in [35S]-GTPγS binding than SKF38393 (figure 4). Dihy-
drexidine gave an EC50 of 43.8 ± 8.23 nM (hD1, figure 4).
A difference between dihydrexidine and SKF38393 was
not observed in intracellular [Ca2+] and [cAMP] measure-
ments (data not shown), and thus SKF38393 was used in
Ca2+ and cAMP studies. The EC50 of quinpirole at hD2L
receptors was estimated as 437 ± 93.1 nM (data not
shown). All LE compounds except LE401 showed an inhi-
bition of [35S]-GTPγS binding between 25 and 40% (not
shown).
None of the tested compounds (neither LE compounds
nor reference compounds haloperidol or clozapine)
showed any agonist effect in functional studies (data not
shown). All test compounds inhibited agonist-stimulated
effects on intracellular [cAMP] and [Ca2+] and on [35S]-
GTPγS binding at D1 or D2L receptors, respectively, in a
concentration-dependent manner. LE400 in Ca2+ studies
and LE401 in all functional assays achieved ≤ 50% inhib-
itory activity at 10 μM. Concentration-inhibition curves of
the most potent novel compounds at D1 and D2L recep-
tors, LE404 and LE410, are displayed in figure 5. Apparent
functional pKi values (pKi app) derived from inhibition
experiments of all compounds in cAMP, Ca2+, and [35S]-
GTPγS studies are presented in table 5. When comparing
pKi values of one compound from cAMP, Ca2+, and [35S]-
GTPγS studies, differences may occur (e.g., clozapine at D1
receptors: pKi(cAMP): 6.46; pKi ([35S]-GTPγS): 7.47) but
also good accordance was observed (e.g., LE404 at D1
receptors: pKi values between 7.95 and 8.20). The rank
orders of potency of the tested compounds at D1 and D2L
receptors, respectively, remained similar for the three
functional assays: the most potent compound at D1 recep-
tors in all three functional assays (table 5) and in binding
(table 2) is LE404 whereas the weakest compounds are
LE400 and LE401. At D2L receptors, LE300, LE410, and
LE404 are the most potent compounds after haloperidol
whereas again, LE400 and LE401 are the weakest (bind-
ing: table 2, functional assays: table 5). LE404 has a 25-
fold selectivity for D1 over D2L receptors based on binding
(table 2). This D1 preference was lost in cAMP and [35S]-
GTPγS experiments (LE404 is ~ equipotent at D1 and D2L)
but a certain D1 preference (3-fold) was retained in Ca2+
studies (table 5). Haloperidol showing a 100-fold D2L
over D1 selectivity in binding (table 2) retained this 100-
fold D2L  selectivity in [35S]-GTPγS experiments but
showed an increased D2L selectivity in cAMP and Ca2+
studies (> 1000-fold). LE410 which displayed an only
moderate D1  selectivity in binding (~2-fold, table 2)
became D2L selective in cAMP and Ca2+ studies but was ~
equipotent in [35S]-GTPγS binding. These results show
that cAMP and Ca2+ studies uprate the potency of com-
pounds at D2L compared to D1 receptors (tables 2 and 5).
Statistical comparison of functional and binding data at D1 
and D2L receptors
The multiple intercorrelation and thus the equality of the
results obtained by binding and the three functional
assays at D1 and D2L receptors, respectively, was deter-
mined by principal component analysis (PCA). Results of
Table 3: Characterization of AHAD11, B157, LERU301, and SH3 
at hD1 receptors used for 3D-QSAR analysis.
Compound
AHAD11 B157 LERU301 SH3
pKi (hD1) 5.82 ± 0.07 6.98 ± 0.05 7.26 ± 0.03 6.17 ± 0.04
Displayed are pKi values ± SEM, n ≥ 3.
Table 2: Characterization of compounds by heterologous competition binding
Compound pKi
hD1 hD2L hD3 hD4.4 hD5 h5HT2A
Haloperidol 6.55 ± 0.09 8.56 ± 0.05 8.00 ± 0.05 8.10 ± 0.04 7.50 ± 0.06 6.84 ± 0.12
Clozapine 6.68 ± 0.03 6.60 ± 0.06 6.13 ± 0.05 6.93 ± 0.08 6.50 ± 0.08 8.23 ± 0.07
LE300 7.98 ± 0.06 7.19 ± 0.04 6.48 ± 0.04 6.46 ± 0.08 7.99 ± 0.05 9.65 ± 0.04
LE400 5.58 ± 0.16 5.90 ± 0.05 5.28 ± 0.07 4.79 ± 0.06 5.44 ± 0.07 6.86 ± 0.13
LE401 4.77 ± 0.25 5.06 ± 0.13 4.83 ± 0.16 < 4a) 4.79 ± 0.50 < 4a)
LE403 7.94 ± 0.06 6.43 ± 0.07 6.14 ± 0.10 6.26 ± 0.06 7.84 ± 0.05 8.40 ± 0.08
LE404 8.47 ± 0.10 7.10 ± 0.05 6.73 ± 0.06 7.23 ± 0.03 8.53 ± 0.09 8.79 ± 0.07
LE410 7.76 ± 0.04 7.54 ± 0.06 6.86 ± 0.07 6.32 ± 0.06 7.78 ± 0.10 8.40 ± 0.10
LE420 6.89 ± 0.07 6.64 ± 0.05 6.07 ± 0.06 5.83 ± 0.11 6.92 ± 0.04 7.97 ± 0.05
a) Displacement of radioligand was < 30% at 10 μM
Haloperidol, clozapine, and LE compounds were characterized at dopamine and h5HT2A receptors. [3H]SCH23390 was used for hD1-like and 
[3H]spiperone for hD2-like and h5HT2A receptors. Displayed are pKi values ± SEM, n ≥ 3.BMC Pharmacology 2006, 6:11 http://www.biomedcentral.com/1471-2210/6/11
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the PCA comparing the four test systems (factor loadings)
are displayed in table 6. The first extracted principal com-
ponent (PC) for D1 receptors described 89.8% of the total
variance among the four pKi variables (cAMP, Ca2+, [35S]-
GTPγS, and binding) with factor loadings > 0.91 (table 6)
leaving an eigenvalue of only 0.237 for the second PC. For
D2L receptors, the first extracted PC explained 97.5% of
the total variance among the four pKi variables (factor
loadings > 0.98, table 6) leaving an eigenvalue of only
0.050 for the second PC. Following the idea that a PC with
an eigenvalue of << 1 has no legitimacy for the description
of the total variance [19], the PCA results indicate a signif-
icant multiple correlation among the four variables for D1
and D2L receptors, respectively.
Nature of antagonism of LE compounds at D1 and D2 
receptors
Next, the nature of antagonism of LE compounds at D1
and D2L receptors was tested by Clark analysis [20]. Since
LE404 was the most potent compound at D1 and LE410
the most potent at D2L receptors (binding, table 2), LE404
and LE410 were chosen as representatives to undergo
functional analysis for competitive antagonism. In the
presence of increasing concentrations of LE404 and
LE410, parallel rightward shifts of the agonist concentra-
tion-effect curves in the Ca2+ assay were observed without
loss of maximum efficacy at hD1 and hD2L receptors (data
not shown). The rightward shift of the concentration-
effect curves of the agonist was analyzed with non-linear
regression analysis according to Lew and Angus [20]. Data
were fitted to equations (1) and (2) (see methods). An F-
Test showed no significant difference (p > 0.2), thus equa-
tion (2) with a Hill slope of 1 was the preferred model and
used to obtain pKb values. Results for LE404 at hD1 and
hD2L receptors are presented in figures 6A and 6B. Inserts
show the Clark plots (mean log EC50 values of the agonist
concentration-effect curves plotted against log ([LE404] +
Kb) which yielded straight lines at both receptor subtypes.
pKb values were calculated as: hD1: pKb LE404 = 8.09 ± 0.15;
pKb LE410 = 7.69 ± 0.13; hD2L: pKb LE404 = 7.61 ± 0.10; pKb
LE410 = 8.05 ± 0.11. pKb values of LE404 and LE410 derived
from non-linear Clark analysis show no significant differ-
ence to those derived from Schild analysis [21] (data not
shown). Both functional analyses (Schild, Clark) give thus
evidence for a competitive antagonistic behaviour of
LE404 and LE410 at D1 and D2L receptors.
Statistical analysis of binding affinities and selectivities at 
dopamine and 5HT2A receptors
In order to perform a statistically valid test for the discov-
ery of ligands with differing affinity profiles at dopamine
D1-D5 and 5HT2A receptors among the examined com-
pounds, multiple intercorrelations of binding affinity val-
ues (pKi, table 2) as well as binding selectivity values [log
(Ki ratio) = log (Ki Receptor 1/Ki Receptor 2)] were investigated
in two separate PCA's. PCA has already successfully been
applied to define similar and deviating responses among
biological data (variables) [22,23]. LE401 was excluded
from both PCA's because precise pKi values were missing
at hD4.4 and h5HT2A receptors (table 2). In the first PCA,
eight compounds were examined (haloperidol, clozapine,
LE300, LE400, LE403, LE404, LE410, and LE420) for their
affinity in six test systems (D1-D5 and 5HT2A receptors).
The PCA resulted in two PC's from which the first
hD1 receptor stimulation of [35S]-GTPγS-binding by dihydrex- idine (●) and SKF38393 (❍) Figure 4
hD1 receptor stimulation of [35S]-GTPγS-binding by 
dihydrexidine (●) and SKF38393 (❍). Both agonists 
were used in HEK293 cell membranes recombinantly 
expressing hD1 receptors in the presence of 1 μM GDP. 
Data shown are means ± SEM of at least three experiments.
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Table 4: EC50 and IC50 values of reference compounds at D1 and D2L receptors in functional studies.
Agonist Antagonist
Assay Receptor SKF38393 Quinpirole LE300 Haloperidol
[cAMP] hD1 33.0 ± 4.01 123 ± 31.1
hD2L 9.61 ± 3.31 1.54 ± 0.39
[Ca2+]h D 1 24.5 ± 4.19 718 ± 168
hD2L 8.62 ± 2.66 0.30 ± 0.10
Data shown are EC50/IC50 values in nM ± SEM, n ≥ 3.BMC Pharmacology 2006, 6:11 http://www.biomedcentral.com/1471-2210/6/11
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extracted 80.5% of the total variance among the eight pKi
variables, and the second extracted 11.4%. The factor
loadings of the eight variables (compounds) are listed in
table 7 and show that the eight compounds define three
subgroups of dopamine/5HT2A  ligands: 1) clozapine,
LE300, LE400, LE410, and LE420 with factor loadings
contributing to the first PC of > 0.739; 2) haloperidol in
the second PC with a factor loading of -0.923; 3) LE403
and LE404 in the second PC with opposite direction to
haloperidol (factor loadings 0.868 and 0.886) indicating
that LE403 and LE404 display an affinity profile opposite
to that of haloperidol. For the second PCA, for each of the
eight compounds, log (Ki ratio) values [= log (Ki Receptor 1/
Ki Receptor 2)] were calculated for all possible 15 receptor
affinity ratios (D1/D2L, D1/D3, D1/D4.4, D1/D5, D1/5HT2A,
D2L/D3, D2L/D4.4, D2L/D5, D2L/5HT2A, D3/D4.4, D3/D5, D3/
5HT2A, D4.4/D5, D4.4/5HT2A, D5/5HT2A) using the data
from table 2. The resulting log (Ki ratio) data matrix con-
tains selectivity information for each of the compounds.
Results of this second ("selectivity") PCA were basically
identical to results from the first ("affinity") PCA (table
7). The first extracted PC explained 74.8% of the total var-
iance among the eight variables (log (Ki ratio) values), and
the second PC extracted 15.4% of the total variance. The
second ("selectivity") PCA discovered the same three sub-
groups of dopamine/5HT2A ligands as did the first PCA: 1)
clozapine, LE300, LE400, LE410, and LE420 with factor
loadings contributing to the first PC of > 0.780 (table 7);
2) haloperidol in the second PC with a factor loading of -
0.901; 3) LE403 and LE404 in the second PC with oppo-
site direction to haloperidol (factor loadings 0.933 and
0.893). Thus, regardless of using affinity  information
(pKi) or selectivity information (log (Ki ratio)) for PCA,
the same three subgroups of dopamine/5HT2A ligands
were discriminated. The agreeing results from both PCA's
underline that the statistical analysis of binding affinities
and selectivities at dopamine and 5HT2A receptors did not
create chance correlations.
3D-QSAR (CoMFA/CoMSIA studies)
Since the main feature of the LE compounds is their D1
selectivity, a 3D-QSAR pharmacophore model for the D1
receptor was establish using the 12 compounds shown in
figure 1 and their D1-pKi values from table 2 and 3. For a
successful CoMFA/CoMSIA study, it is crucial to find an
appropriate alignment of the examined compounds. It is
not necessary that all compounds possess the bioactive
conformation but it is useful that the compounds adopt a
relative conformation and position to each other as they
would bind to the receptor. The D1/D5 selective antagonist
(-)-2b-SCH39166 (ecopipam) was taken as a pharma-
cophore template. (-)-2b-SCH39166 is a benzonapht-
hazepine, a rigid analogue of SCH23390, thus limiting
the number of possible conformations (figure 7) [24].
Unfortunately, (-)-2b-SCH39166 was not available to us
for testing, and was thus not used for the final QSAR-anal-
ysis. However, due to its rigid nature, it was helpful to find
a good starting point for selecting conformations and
alignments of the 12 compounds from figure 1. Essential
pharmacophore features of (-)-2b-SCH39166 are the two
aromatic rings and the basic nitrogen (hydrogen acceptor)
while the hydroxyl group served as an optional H-donor/
acceptor feature (figure 7). Results of the alignment of the
final models of the LE compounds are shown in figure 8.
The aromatic residues and basic nitrogen atoms remain
the main pharmacophore features. Crossvalidation results
(leave-one-out) for the final models for CoMFA and CoM-
SIA both using steric and electrostatic fields are displayed
in table 8, and show crossvalidation parameters q2 of 0.82
for CoMFA and 0.88 for CoMSIA. To prove that these
models were not a result of a chance correlation, a stabil-
ity test was performed using the random groups PLS
Table 5: Inhibitory potencies of the LE compounds on agonist-induced effects on [cAMP]i, [Ca2+]i, and [35S]-GTPγS binding
pKi app
Compound [cAMP]i [Ca2+]i [35S]-GTPγ S binding
hD1 hD2L hD1 hD2L hD1 hD2L
Haloperidol 6.80 ± 0.10 9.88 ± 0.07 6.61 ± 0.09 10.0 ± 0.13 7.10 ± 0.91 9.10 ± 0.07
Clozapine 6.46 ± 0.05 7.30 ± 0.07 6.54 ± 0.15 6.92 ± 0.11 7.47 ± 0.29 7.48 ± 0.08
LE300 7.55 ± 0.13 8.73 ± 0.10 7.22 ± 0.15 7.93 ± 0.12 7.75 ± 0.12 8.14 ± 0.11
LE400 5.35 ± 0.17 6.88 ± 0.09 < 5.00a) < 5.00a) 6.25 ± 0.13 6.39 ± 0.14
LE401 5.00 ± 0.13 < 5.00a) < 5.00a) < 5.00a) < 5.00a) < 5.00a)
LE403 7.02 ± 0.09 7.23 ± 0.12 7.57 ± 0.11 7.14 ± 0.08 7.48 ± 0.12 7.20 ± 0.15
LE404 7.95 ± 0.09 8.01 ± 0.08 8.20 ± 0.15 7.71 ± 0.01 8.10 ± 0.13 8.13 ± 0.08
LE410 7.35 ± 0.12 8.63 ± 0.07 7.39 ± 0.07 8.13 ± 0.11 8.02 ± 0.08 8.13 ± 0.09
LE420 6.44 ± 0.21 7.69 ± 0.08 6.73 ± 0.09 7.08 ± 0.12 7.17 ± 0.11 7.51 ± 0.08
a) Inhibitory activity was ≤ 50% at 10 μM.
Concentration-effect curves were obtained with hD1 and hD2L receptors. Data shown are apparent pKi values (pKi app) ± SEM, n ≥ 3.BMC Pharmacology 2006, 6:11 http://www.biomedcentral.com/1471-2210/6/11
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Functional characterisation of LE404 (■) and LE410 (●) at hD1 (A, B, C) and hD2L receptors (D, E, F) Figure 5
Functional characterisation of LE404 (■) and LE410 (●) at hD1 (A, B, C) and hD2L receptors (D, E, F). A Inhibi-
tion by LE404 and LE410 of 100 nM SKF38393-stimulated accumulation of intracellular [cAMP]. Data shown are means ± SEM 
of at least four determinations assayed in triplicate. B Inhibition by LE404 and LE410 of 100 nM SKF38393-stimulated increase 
in intracellular [Ca2+]. Data shown are means ± SEM of at least four determinations assayed in triplicate. C Inhibition by LE404 
and LE410 of G-protein activation obtained by 1 μM dihydrexidine-stimulation. Data shown are means ± SEM of two independ-
ent experiments assayed in duplicate. D Inhibition by LE404 and LE410 of 100 nM quinpirole-stimulated decrease of intracellu-
lar [cAMP] in the presence of 10 μM forskolin. Data shown are means ± SEM of at least four determinations assayed in 
triplicate. E Inhibition by LE404 and LE410 of 30 nM quinpirole-stimulated increase in intracellular [Ca2+]. Data shown are 
means ± SEM of at least four determinations assayed in triplicate. F Inhibition by LE404 and LE410 of G-protein activation 
obtained by 10 μM quinpirole-stimulation. Data shown are means of two independent experiments assayed in duplicate.
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method ("leave-many-out"). The test showed a high sta-
bility of the models presented in figure 8 with a mean q2
of 0.76 (SD 0.10) for the combined steric and electrostatic
field in CoMFA and a mean q2 of 0.81 (SD 0.12) in CoM-
SIA. The distribution of the q2 values for this validation is
shown in figure 9.
Discussion
Among a group of new azecine compounds, this study has
revealed two dibenzacezines (LE404 and LE410) with
potent activity at dopamine and 5HT2A receptors display-
ing a novel receptor profile at D1-D5 and 5HT2A receptors.
Compounds were evaluated in binding studies at D1-D5
and 5HT2A receptors and functionally (cAMP, Ca2+, [35S]-
GTPγS) at D1 and D2L receptors, representative for the two
subgroups of Gs  (D1-like) and Gi  (D2-like) coupled
dopamine receptors. PCA revealed the equivalence of
functional and binding pKi values (table 6) even though
binding, cAMP, Ca2+, and [35S]-GTPγS assays differ
strongly in the applied conditions (equilibrium: binding,
cAMP, [35S]-GTPγS; non-equilibrium: Ca2+) and used end-
points (competition binding, G protein activation, second
[cAMP] and "third" [Ca2+] messenger generation). A com-
parison of pKi values of one compound in the four differ-
ent assays thus leads to differences, e.g., Ki  ratios of
haloperidol at D1/D2L  receptors are ~1200 in cAMP,
~2500 in Ca2+, and ~100 in [35S]-GTPγS and binding stud-
ies but the rank order of potency remains almost
unchanged (tables 2 and 5). Mottola et al. [25] have intro-
duced the term "functional selectivity" to propose that
depending on the experimental (buffer, equilibrium) and
cellular conditions regarding receptor and G protein
expression, a mixture of agonist/partial agonist and/or
antagonist actions are likely. The ~2-fold difference in D1
and D2L receptor expression in this study (table 1) may
thus contribute to differences in pKi values observed in
functional and binding studies. The same reasons may
serve as an explanation for differences in the Kd values of
SCH23390 and spiperone in this study and in the litera-
ture (table 1) and for the ~1.4–5.5-fold differences in the
affinity of LE300 in this and a previous study [11]. Fur-
ther, affinities in this study were tested at recombinantly
expressed receptors in HEK293 cell membranes in Krebs-
HEPES-buffer whereas the previous study used CHO cell
membranes in a Tris-Mg2+-buffer [11]. As was shown in
figure 2, different buffers can result in significantly differ-
ent affinity of a ligand.
LE404 and LE410 are competitive antagonists as was
shown by Clark analysis (figure 6). pKb values of LE404
and LE410 derived from these functional analyses are in
accordance with pKi values derived from inhibition curves
(tables 5 and 2). Statistical analysis (PCA) of binding
affinity data (pKi values, table 2) and binding selectivity
data [log (Ki  ratio) values, calculated from table 2]
Functional analysis of the antagonist effect of LE404 at hD1  and hD2L receptors Figure 6
Functional analysis of the antagonist effect of LE404 
at hD1 and hD2L receptors. The analysis was carried out 
by measuring the attenuation by LE404 of the agonist-
induced increase in intracellular [Ca2+] in HEK293 cells 
recombinantly expressing hD1 and hD2L receptors, respec-
tively. Dashed lines show 95% confidence intervals. 
SKF38393 was used as agonist at hD1 receptors, quinpirole at 
hD2L. All slopes were not significantly different from unity. 
Presented data are means ± SEM from at least three inde-
pendent experiments each with at least threereplicates. A, 
B. Clark analysis of LE404 at hD1 (A) and hD2L receptors (B). 
Inserts show Clark plots.
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resulted in three groups of ligands: first: haloperidol; sec-
ond: clozapine, LE300, LE400, LE410, and LE420; and –
interestingly – a third group: containing LE403 and LE404
(table 7). The most potent compounds in group 2 and
group 3 are LE410 and LE404. LE410 has a similar affinity
profile as clozapine except the lower potency of LE410 at
the hD4.4 receptor (table 2). In contrast, LE404 has a 25-
fold selectivity for D1 over D2L receptors and thus a novel
dopamine/5HT2A receptor profile. Interestingly, if instead
of all Ki ratio values which have been used for the PCA in
table 7 only the D1/D2L and D2L/5HT2A ratios of all com-
pounds were used for clustering, the same three groups
were found: 1) haloperidol, 2) clozapine, LE400, LE410,
LE420, LE300, and 3) LE403 and LE404 (table 9). Thus,
instead of six receptors and 15 Ki ratios, a reduction to
three receptors (D1, D2L, 5HT2A) and two Ki ratios is suffi-
cient to obtain the same clustering of compounds.
Meltzer et al. suggested the use of D1/D2L and D2L/5HT2A
ratios to allow a clustering of antipsychotics into typical
and atypical compounds [5-7]. However, instead of Melt-
zer et al. who calculated pKi ratio values which are impre-
cise in defining selectivity (same selectivity may result in
different pKi ratios depending on the potency), Ki ratios
(table 9) or log (Ki ratio) values (for PCA in table 7) were
calculated in this study. Ki ratios recalculated from data of
Meltzer et al. [5] and Ki ratios from this study were no
more different than 3-fold (table 9). LE300, LE403,
LE404, LE410, and LE420 achieved Ki-D2/Ki-5HT2A selectiv-
ity ratios > 7 which may suggest an atypical behaviour of
these compounds according to Meltzer et al. [5]. However,
so far there are no in vivo behavioural studies underlying
an antipsychotic effect of the LE compounds. The third
group of ligands, LE403 and LE404, differ from LE410 by
a 15-20-fold increase in D1 selectivity (table 9). RMI-
81582 has very similar D1/D2 and D2/5HT2A Ki ratios as
LE403 and LE404 (table 9) and was shown to exert antip-
sychotic effects [26]. A further increase in D1 selectivity
over D2, e.g., compound SCH23390 (table 9), results in a
complete loss of antipsychotic activity [5,9,10]. Therefore,
LE403 and LE404 might display an antipsychotic effect
which however needs to be proven in in vivo studies. Only
in vivo studies take into account the complexity of neu-
ropsychiatric diseases including expression, distribution,
and regulation of multiple receptors as well as adaptive
processes.
This study confirmed recent findings that an increase in
the size of the residue of the azecine nitrogen is detrimen-
tal to the affinity at dopamine/5HT2A receptors (table 2)
[11]. Hydroxylated versus non-hydroxylated dibenza-
cezines differ in their affinity and selectivity profiles
(LE410, LE404, table 2) and define 2 separate groups.
Monohydroxylation (LE404) results in higher potency
than bis-hydroxylated compounds (LE403). Abolishing
the H-donor properties by exchanging hydroxyl by meth-
oxy groups was detrimental to the potency (LE400 versus
LE403). Binding data of all compounds in figure 1 have
been used to establish a valid 3D-QSAR pharmacophore
model for D1 receptors (figure 8). The resulting model
shows excellent q2 values for crossvalidation results and
random groups PLS tests for both, CoMFA and CoMSIA
(figure 9) excluding a chance correlation. The pharma-
cophore model is thus a solid basis for further improve-
ment of dopamine receptor ligands.
Table 7: PCA results of affinity and selectivity data at dopamine and 5HT2A receptors
Variable pKi log (Ki Receptor 1/Ki Receptor 2)
1st Principal Component 2nd Principal Component 1st Principal Component 2nd Principal Component
Haloperidol -0.205 -0.923 -0.272 -0.901
Clozapine 0.796 0.260 0.780 0.356
LE300 0.775 0.629 0.921 0.354
LE400 0.955 0.222 0.983 0.122
LE403 0.488 0.868 0.290 0.933
LE404 0.410 0.886 0.395 0.893
LE410 0.739 0.568 0.840 0.433
LE420 0.829 0.549 0.873 0.474
The first PCA is using pKi values from table 2 (affinity information), the second log (Ki ratio) values (selectivity information). Log (Ki ratio) values 
[= log (Ki Receptor 1/Ki Receptor 2)] were calculated for all possible 15 receptor affinity ratios using data from table 2. Displayed are factor loadings for 
the first two PC's after Varimax rotation.
Table 6: Factor loadings of the four variables used in principal 
component analysis
Variable hD1 hD2L
cAMP 0.953 0.985
Ca2+ 0.955 0.986
[35S]-GTPγS 0.913 0.985
radioligand binding 0.970 0.994BMC Pharmacology 2006, 6:11 http://www.biomedcentral.com/1471-2210/6/11
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Conclusion
In conclusion, this study has revealed two compounds,
the dibenzacezines LE410 and LE404 with a novel
dopamine/5HT2A receptor profile. LE404 and LE410 differ
in their D1/D2L selectivity. LE410 clusters in one group
with the atypical antipsychotic clozapine but has a differ-
ent D2-like receptor profile (hD2L > hD3 > hD4.4) than
clozapine (hD4.4 > hD2L > hD3). LE404 clusters in a sepa-
rate group from clozapine/LE410 and from haloperidol
and shows increased D1 selectivity similar to the experi-
mental compound RMI-81582 which displayed antipsy-
chotic activity [26]. An antipsychotic activity of LE404 and
LE410 in in vivo studies still needs to be shown. Further, a
validated 3D-QSAR pharmacophore model for D1 antago-
nists is presented.
Methods
Materials
LE300, 400, 401, 403, 404, 410, and 420 were synthesized
according to methods previously published [11,13].
[3H]SCH23390 (66.0 Ci/mmol), [3H]spiperone (118 Ci/
mmol), and [35S]-GTPγS were obtained from Amersham
Biosciences (Buckinghamshire, UK). SKF38393 was pur-
chased from TOCRIS (Bristol, U.K.). A pRc/CMV vector
construct for hD3 receptors was kindly provided by Dr. P.
Sokoloff (Paris, France) [27] and a pcDNA3.1+ construct
containing cDNA coding for the h5HT2A receptor was
obtained from the UMR cDNA resource center [28]. All
other reagents were supplied by Sigma Chemicals unless
otherwise stated.
Cell culture
HEK293 cells stably expressing hD1, hD2L, or hD5
dopamine receptors were established as previously
described [11,29]. Stable cell lines of HEK293 cells
(ATCC, Rockville, MD, USA) were generated by transfect-
ing the plasmids coding for hD3 and h5HT2A using poly-
fect®  transfection reagent (Qiagen, Hilden, Germany)
according to the manufacturer's instructions and were
Table 8: Crossvalidation results for the final alignment models of the LE compounds
Field Minimum σ No of components SDEP* q2
CoMFA 0.75 3 0.60 0.82
CoMSIA 0.75 3 0.50 0.88
* SDEP: standard error of prediction
The models are displayed in figure 8 using steric and electrostatic fields for both CoMFA and CoMSIA.
3D model of (-)-2b-SCH39166 with H-donor/acceptor and  aromatic features Figure 7
3D model of (-)-2b-SCH39166 with H-donor/acceptor 
and aromatic features. This model was used as pharma-
cophore-template for the LE compounds. Alignment of the final 3D-QSAR models of the LE com- pounds Figure 8
Alignment of the final 3D-QSAR models of the LE com-
pounds.BMC Pharmacology 2006, 6:11 http://www.biomedcentral.com/1471-2210/6/11
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selected using G-418 (400 μg/ml medium). All stably
transfected cell lines were grown in Dulbecco's modified
Eagle Medium Nutrient Mixture F-12 Ham (DMEM/F12
1:1 mixture) containing 10% fetal bovine serum, 100 μg/
ml streptomycine, 100 U/ml penicillin G, 5 mM L-
glutamine, and 200 μg/ml active G-418. The human D4.4
receptor was stably expressed in CHO cells (kindly pro-
vided by Dr. van Tol, Toronto, Canada) and grown in
Ham F12 medium supplemented with 10% fetal bovine
serum, 100 μg/ml streptomycin, 100 U/ml penicillin G, 1
mM L-glutamine, and 200 μg/ml active G-418. Cells were
incubated at 37°C in a humidified atmosphere under 5%
CO2.
Membrane preparation
Confluent 145 mm tissue culture dishes (Greiner Bio-
One, Frickenhausen, Germany) of HEK293 or CHO cells
were harvested by scraping, resuspended in ice-cold
Krebs-HEPES buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM
MgSO4, 1.2 mM KH2PO4, 4.2 mM NaHCO3, 11.7 mM D-
Glucose, 1.3 mM CaCl2, 10 mM HEPES, pH 7.4), and dis-
rupted using a Polytron homogenizer on ice (Kinematica
AG, Basel, Switzerland). After centrifugation at 40,000 × g
at 2°C, the supernatant was discarded, and pellet was
washed twice with ice-cold Krebs-HEPES buffer. Eventu-
ally, the pellet was resuspended in the appropriate bind-
ing buffer (see below) and stored in aliquots at -80°C
until use for radioligand binding. The method of Bradford
[30] was used to determine the protein content of mem-
brane preparations with bovine serum albumin as stand-
ard.
For [35S]-GTPγS-binding, cell pellets were resuspended in
10 mM Tris-HCl/1 mM EDTA, pH 7.4, homogenized in a
glass-teflon homogenizer and centrifuged for 15 min
(40,000 × g, 4°C). Supernatant was discarded, and pellet
was washed twice with ice-cold Tris-HCl/EDTA buffer and
finally resuspended in 50 mM Tris-HCl, 4 mM MgCl2, 1
mM EDTA, 250 mM sucrose, pH 7.4, and stored at -80°C.
The protein content was determined according to the
Bradford method [30] with gamma immunoglobulin as
standard.
Radioligand binding experiments
The equilibrium dissociation constants Kd of the radiolig-
ands used ([3H]SCH23390 for hD1-like, [3H]spiperone
for hD2L-like and h5HT2A receptors) were determined in
homologous competition binding experiments and recep-
tor densities of the respective dopamine receptor cell
membrane preparations (Bmax  values) were calculated
Table 9: Ki ratio values (Ki-D1/Ki-D2 and Ki-D2/Ki-5HT2A) of all test 
compounds except LE401
Compound Ki-D1/Ki-D2 Ki-D2/Ki-5HT2A
Haloperidol 102 (100a)) 0.02 (0.05a))
Clozapine 0.83 (1.58a)) 42.6 (19.95a))
LE400 2.09 9.12
LE410 0.60 7.24
LE420 0.56 21.4
LE300 0.16 294
LE403 0.03 93.5
LE404 0.04 49.0
RMI-81582 0.05a) 31.6a)
SCH23390 0.0004b) 50.0c)
a) Value is calculated from [6].
b) Value is calculated from [33,34].
c) Value is calculated from [34,35].
Further, data for SCH23390 and RMI-81582 are calculated from 
literature data. Ki values used are derived from radioligand binding 
studies.
Validation of the final alignment models using the random  groups PLS method ("leave-many-out") Figure 9
Validation of the final alignment models using the 
random groups PLS method ("leave-many-out"). A. 
CoMFA field. B. CoMSIA field.
A
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using the DeBlasi equation [31]. Heterologous competi-
tion binding experiments were performed in Krebs-
HEPES buffer in a final volume of 1.1 ml at 26°C for 2 h
(D1-like receptors) or 3 h (D2-like receptors and 5HT2A
receptors) as described previously [11]. Cell membranes
(total protein amount ~90 μg/tube) were incubated with
0.2 nM final [3H]SCH23390 (D1-like receptors) or with
0.1 nM final [3H]spiperone (D2-like receptors and 5HT2A
receptors) and competing drugs. The assay was terminated
by rapid filtration of 1 ml through polyethylene imine
pretreated (0.2%) glass fiber filters (Schleicher und
Schuell, Dassel, Germany), followed by two washes with
ice-cold distilled water. Filters were soaked in 5 ml of scin-
tillation fluid for at least 12 h and bound radioactivity was
determined by liquid scintillation counting. Nonspecific
binding of [3H]SCH23390 was determined in the pres-
ence of 1 μM LE300, nonspecific binding of [3H]spiper-
one in the presence of 1 μM haloperidol for hD2L-like
receptors and 1 μM ketanserin for h5HT2A  receptors.
Estimation of [35S]-GTPγS-binding in HEK293 membranes
Cell membranes (for hD1: total protein amount ~16 μg,
~1.5 pmol receptor/mg protein; for hD2L: total protein
amount ~16 μg, ~0.3 pmol receptor/mg protein) were
incubated with test compounds, 1 μM GDP, agonist (1
μM dihydrexidine for hD1, 10 μM quinpirole for hD2L)
and 100 pM [35S]-GTPγS in microplates in a total volume
of 200 μl assay buffer (20 mM HEPES-NaOH (pH 7.4),
100 mM NaCl, 3 mM MgCl2). Plates were incubated for
60 min at 30°C. Reaction was terminated by rapid vac-
uum filtration through GF/C filter plates (PerkinElmer),
and filter plates were washed four times with 200 μl Tris-
HCl (pH 7.4). Radioactivity retained on the filter plates
was counted in a microplate counter (Microbeta, Perk-
inElmer).
Measurement of changes in intracellular [Ca2+] in HEK293 
cells
Measurement of changes in intracellular [Ca2+] was per-
formed as previously described using a NOVOstar micro-
plate reader with a built-in pipetor (BMG LabTech,
Offenburg, Germany) [11]. HEK293 cells expressing the
respective dopamine receptor were loaded with 3 μM Ore-
gon Green 488 BAPTA-1/AM (Molecular Probes, Eugene,
OR) for 1 h at 25°C in Krebs-HEPES buffer containing 1%
Pluronic F-127. Then, cells were rinsed three times with
Krebs-HEPES buffer containing 0.5% bovine serum albu-
min, diluted, and evenly plated into 96 well plates
(Greiner, Frickenhausen, Germany) at a density of
~35,000 cells/well. Microplates were kept at 37°C. Fluo-
rescence intensity was measured at 520 nm (bandwidth
35 nm) for 5 s at 0.4 s intervals to monitore baseline.
Buffer alone or test compounds dissolved in buffer were
then injected into separate wells, and fluorescence inten-
sity was monitored at 520 nm (bandwidth 35 nm) for 25
s at 0.4 s intervals. Excitation wavelength was 485 nm
(bandwidth 12 nm). Concentration-inhibition curves in
the presence of the test compounds were obtained by pre-
incubating the cells with the compounds for 30 min at
37°C prior to injection of agonist (hD1: 100 nM
SKF38393; hD2L: 30 nM quinpirole).
Measurement of changes in intracellular [cAMP] in 
HEK293 cells
Intracellular [cAMP] levels were estimated by using a
cAMP reporter gene assay. pCRE-Luc Cis-Reporter plas-
mid (Path Detect® CRE Cis-Reporting System, Stratagene,
La Jolla, CA) coding for the firefly luciferase under the
control of a cAMP response element was transiently trans-
fected in HEK293 cells stably expressing the hD1 or hD2L
receptor. 24 h after transfection, cells were reseeded in
poly-L-lysine-coated (Biochrom, Berlin, Germany) white
96-well plates with clear bottom (Greiner, Frickenhausen,
Germany) at a density of ~25,000 cells/well. Microplates
were incubated for 48 h at 37°C and 5% CO2 before using
the cells for adenylyl cyclase stimulation or inhibition
experiments. Cells were then exposed to increasing con-
centrations of test compounds dissolved in serum-free
and phenol red-free medium and incubated for 3 h at
37°C and 5% CO2. In case of hD2L, 10 μM forskolin was
added. Antagonistic activity was tested by pre-incubation
of test compounds for 30 min at 37°C and 5% CO2 prior
to the addition of agonist (hD1: 100 nM SKF38393; hD2L:
100 nM quinpirole plus 10 μM forskolin) for 3 h. Incuba-
tion was terminated by adding 100 μl of cell lysis buffer (8
mM tricine, 1 mM dithiothreitol, 2 mM EDTA, 5 % Triton®
X-100, pH 7.8) for 20 min at 4°C. Luciferase activities
were measured with the LUMIstar microplate reader
(BMG LabTech, Offenburg, Germany). After monitoring
the baseline for 0.3 s, 100 μl of luciferase assay reagent (30
mM tricine, 0.5 mM ATP, 10 mM MgSO4, 0.5 mM EDTA,
10 mM dithiothreitol, 0.5 mM coenzyme A, 0.5 mM D-
luciferin, pH 7.8) was added and luminescence was meas-
ured at 25°C for 12.7 s at 0.1 s intervals. Luminescence
was corrected by subtracting baseline levels.
Functional analysis of antagonism
Functional analysis of the antagonist effect of LE404 and
LE410 was carried out by measuring the attenuation by
LE404 or LE410 of the agonist-induced increase in intrac-
ellular [Ca2+] in HEK293 cells recombinantly expressing
hD1 or hD2L receptors. At least four antagonist concentra-
tions were used. Functional data were used for nonlinear
regression analysis according to Clark [20]. The pEC50 val-
ues of the agonist curves were plotted against the concen-
tration of test compounds LE404 or LE410 and analyzed
by non-linear regression curve fitting using the following
equations:
(1) pEC50 = -log ([B]n + 10-pKb) - log cBMC Pharmacology 2006, 6:11 http://www.biomedcentral.com/1471-2210/6/11
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(2) pEC50 = -log ([B] + 10-pKb) - log c
where [B] is the concentration of antagonist (LE404 or
LE410), pKb is the negative decadic logarithm of the antag-
onist dissociation constant, n the Hill coefficient, and log
c the difference between the pKb and the pEC50 value of
the agonist concentration-response curve in absence of
the antagonist. Fits to equations (1) and (2) were com-
pared by an F-test.
Data analysis
Radioligand-binding and functional data (measurement
of intracellular [Ca2+], [cAMP], and [35S]GTPγS binding)
were analyzed by fitting the pooled data from at least
three experiments (each with three replicates) to the four
parameter logistic equation using Prism software 3.0 from
GraphPad (GraphPad Software; San Diego, CA, USA).
Competition-binding experiments were fitted best to a
one-site binding model. Inhibition constants Ki from radi-
oligand binding competition experiments were calculated
from IC50 values using the Cheng-Prusoff equation [32].
Apparent functional Ki values were calculated according to
the following equation adapted from Cheng and Prusoff
[32]:
Ki = IC50/(1+L/EC50)
where IC50 is the inhibitory concentration of the antago-
nist to block by 50% the agonist effect, EC50 is the effective
concentration 50% of the used agonist (i.e., SKF38393 for
hD1, and quinpirole for hD2L receptors), and L is the
molar concentration of the used agonist. Data (data
points in figures and numbers in tables) are given as mean
± SEM of at least three independent experiments each per-
formed with triplicates unless otherwise stated. Statistical
analyses including principal component analysis were
performed using SPSS (version 12.0.1 for Windows).
3D-QSAR (CoMFA/CoMSIA) studies
All calculations were carried out on an x86-compatible PC
running SuSE-Linux 9.2. For molecular modelling, SYBYL
7.0 (Tripos Inc., St. Louis, Missouri, USA) and MOE
2004.03 for Linux (Chemical Computing Group Inc.,
Montreal, Quebec, Canada) were used. Conformational
clustering was done using MATLAB Release 13 for Linux
(The MathWorks Inc., Natick, MA, USA). Conformational
analyses of all 12 compounds from figure 1 were done
using a repeated molecular dynamics based simulated
annealing approach as implemented in SYBYL 7.0.
MMFF94 served as the force field with distance dependent
electrostatics. A molecule was heated up to 1000 K within
2000 fs, held at this temperature for 2000 fs and annealed
to 0 K for 10000 fs using an exponential annealing func-
tion. By applying this procedure, a total of 100 conforma-
tions were sampled during 100 cycles to account for
conformational flexibility and to find the most likely con-
formations occurring most often in the resulting pool.
This was done for both configurations of the protonated
nitrogen atom because molecular mechanics is not able to
switch configurations. All conformations were then opti-
mized with the semi-empirical quantum mechanics
method AM1 as implemented in MOPAC 6 from SYBYL
and further compared using the SYBYL MATCH algo-
rithm. Subsequently, a MATLAB clustering algorithm was
used to extract the most divergent conformations using
the root mean square (RMS) values of the comparison and
the AM1 heat of formation. The most diverse and most
often represented conformations of each compound were
selected and overlaid with the pharmacophore resulting
from the rigid ligand (-)-2b-SCH-39166 using the pro-
gram MOE. The best 2–4 matched alignments per com-
pound were selected for the CoMFA/CoMSIA study upon
minimum RMS criteria and visual examination. These
conformations were transferred to a SYBYL database and
used as an initial alignment for the CoMFA/CoMSIA
study. During an automated procedure, all possible com-
binations were tested on the CoMFA and CoMSIA com-
bined steric/electrostatic fields with partial least squares
analysis (PLS). In subsequent PLS analyses, the alignment
was refined and the CoMFA/CoMSIA models were opti-
mized. To prove that these models were not a result of a
chance correlation, a stability test was performed using
the random groups PLS method. Within this method,
cross-validation was done with groups of more than one
compound, which were excluded earlier during the
model-building regression. Unlike the leave-one-out
cross-validation, these groups are selected on a random
basis and instead of twelve cross-validation groups, only
five were used. Because of the random selection of the
group members, this cross-validation was repeated a hun-
dred times.
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